Last reviewed · How we verify
Piperacillin/Tazobactam Intermittent infusion
Piperacillin/tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.
Piperacillin/tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation. Used for Bacterial infections caused by susceptible organisms including Gram-negative and Gram-positive aerobic bacteria and anaerobes, Hospital-acquired and community-acquired pneumonia, Intra-abdominal infections.
At a glance
| Generic name | Piperacillin/Tazobactam Intermittent infusion |
|---|---|
| Also known as | Piprataz injection |
| Sponsor | Ain Shams University |
| Drug class | Beta-lactam/beta-lactamase inhibitor combination |
| Target | Penicillin-binding proteins (PBPs); bacterial beta-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Piperacillin is an extended-spectrum penicillin that binds to penicillin-binding proteins and disrupts bacterial cell wall cross-linking, leading to cell lysis and death. Tazobactam is a beta-lactamase inhibitor that irreversibly binds to and inactivates bacterial beta-lactamases, preventing enzymatic degradation of piperacillin and extending its spectrum to include beta-lactamase-producing organisms. The intermittent infusion formulation delivers the combination intravenously over 20-30 minutes at regular intervals.
Approved indications
- Bacterial infections caused by susceptible organisms including Gram-negative and Gram-positive aerobic bacteria and anaerobes
- Hospital-acquired and community-acquired pneumonia
- Intra-abdominal infections
- Urinary tract infections
- Skin and soft tissue infections
- Febrile neutropenia
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Phlebitis at infusion site
- Headache
- Allergic reactions/anaphylaxis
- Clostridioides difficile infection
Key clinical trials
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients (PHASE4)
- Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (PHASE4)
- BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia (PHASE4)
- Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia (PHASE4)
- Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis (PHASE4)
- Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis (NA)
- Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: